Myeloid Blood Cancer Treatment Market Outlook:
Myeloid Blood Cancer Treatment Market size was over USD 12.4 billion in 2024 and is estimated to reach USD 29.1 billion by the end of 2037, exhibiting a CAGR of 8.9% during the forecast period, i.e., 2025-2037. In 2025, the industry size of myeloid blood cancer treatment is estimated at USD 13.4 billion.
According to the report published by the World Health Organization, cases of chronic myeloid leukemia are rising, that already diagnosed approximately 250,500 cases worldwide. The growing cases of myeloid leukemia has created a significant demand for the market. Besides, the expansion of Medicare coverage has increased the accessibility rate and led to robust development in revenue accumulation. According to the data published by the National Institute of Health, more than USD 2 billion is contributed to advanced research on blood cancer.
The supply chain management often experiences constraints due to high demand in the global market. Small molecule required for the production of API is supplied mainly by India and China. This leads the U.S. and EU to import more than 40% of their tyrosine kinase inhibitor (TKIs). According to the report published by the U.S. Bureau of Labor Statistics, the producer price index (PPI) rose 6.9% and the consumer price index increased by 9.3% in 2024 for targeted therapies. High demand in the market, as per the data analytics, often leads to a shortage of raw material and a rise of the product. Approval timing as per the EMA fast-tracked four myeloid treatments in Europe is reduced to less than 45%, which elevated manufacturing scalability.
